LS
VRTX icon

Leelyn Smith’s Vertex Pharmaceuticals VRTX Stock Holding History

Leelyn Smith’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-473
Closed -$220K – 138
2024
Q3 		$220K Sell
473
-5
-1% -$2.4K 0.04% 121
2024
Q2 		$224K Sell
478
-13
-3% -$5.64K 0.04% 117
2024
Q1 		$205K Buy
+491
New +$208K 0.04% 124
2023
Q3 		– Sell
-853
Closed -$300K – 119
2023
Q2 		$300K Sell
853
-172
-17% -$58K 0.07% 103
2023
Q1 		$323K Sell
1,025
-840
-45% -$252K 0.08% 102
2022
Q4 		$303K Buy
1,865
+1,049
+129% +$320K 0.08% 103
2022
Q3 		$236K Sell
816
-1,826
-69% -$525K 0.08% 99
2022
Q2 		$744K Sell
2,642
-2,254
-46% -$603K 0.19% 82
2022
Q1 		$1.28M Buy
4,896
+146
+3% +$34.6K 0.33% 69
2021
Q4 		$1.04M Buy
4,750
+551
+13% +$107K 0.28% 78
2021
Q3 		$762K Buy
4,199
+69
+2% +$13.5K 0.22% 81
2021
Q2 		$833K Sell
4,130
-587
-12% -$123K 0.25% 78
2021
Q1 		$1.01M Buy
+4,717
New +$1.04M 0.3% 77

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Leelyn Smith's VRTX Position: Q4 2024 in Review

Leelyn Smith sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 473 shares — an estimated $220K sold.

Leelyn Smith first reported a position in VRTX in Q1 2021 and held it in 13 quarters. The position peaked at $1.28M in Q1 2022. 1,564 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Leelyn Smith reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Leelyn Smith sold 473 Vertex Pharmaceuticals shares in Q4 2024, an estimated $220K.
  • Leelyn Smith first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Leelyn Smith's Vertex Pharmaceuticals position peaked at $1.28M in Q1 2022.
  • 1,564 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Leelyn Smith's 13F filing for Q4 2024, filed 10 Feb 2025.